{"filings":[{"id":1028285,"accession_number":"0001493152-26-028458","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2026-06-12T20:30:25+00:00","items":["5.07"],"status":"ready","headline":"Abeona shareholders reject removing advance notice provision; approve share reserve increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Goldan and Zeiher elected; say-on-pay and Deloitte auditor ratified.","Increase in shares reserved under 2023 Equity Plan from 8.4M to 11.5M approved with 23.97M for, 5.72M against.","Proposal to remove advance notice provision for director nominations failed (needed 66.67%; got 24.56M for, 4.67M against).","Broker non-votes of 12.26M shares present on director election, say-on-pay, and equity plan proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1009518,"accession_number":"0001493152-26-028369","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2026-06-12T11:30:20+00:00","items":["5.02"],"status":"ready","headline":"Abeona Therapeutics director Michael Amoroso resigns from board for personal reasons","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Amoroso resigned from Abeona's Board effective June 11, 2026.","He also stepped down from the Nominating and Corporate Governance Committee.","Resignation was for personal reasons; no disagreement with company operations.","No replacement named; board size reduced accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":973078,"accession_number":"0001493152-26-028106","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2026-06-10T20:15:44+00:00","items":["7.01","9.01"],"status":"ready","headline":"Abeona furnishes updated investor presentation; no details available","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed an 8-K to furnish an updated investor presentation dated June 10, 2026.","Presentation content not provided; unable to extract specific data or changes.","No financial impact, guidance, or material developments disclosed in the filing.","Presentation intended for use with investors; no other substantive information reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":843158,"accession_number":"0001493152-26-027197","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2026-06-04T11:30:38+00:00","items":["8.01"],"status":"ready","headline":"Abeona holds constructive Pre-IND meeting with FDA for ABO-701; IND target 2027","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Pre-IND meeting with FDA held June 3, 2026 for ABO-701, a T-cell therapy targeting PSMA for prostate cancer.","Company characterizes meeting as constructive; official FDA minutes not yet received.","IND submission for ABO-701 remains targeted for 2027, consistent with prior guidance.","No assurance that FDA will accept IND or that additional studies won't be required.","Development plans subject to revision based on FDA feedback, preclinical results, and manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50165,"accession_number":"0001493152-26-022610","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2026-05-13T11:30:50+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona Q1 net product revenue $8.7M; three ZEVASKYN patients treated; in-licenses PSMA T-cell therapy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue of $8.7M from ZEVASKYN, up from $2.4M in Q4 2025; net loss $17.1M ($0.30/sh).","Cash and investments $168.3M as of March 31, 2026, down from $191.4M at year-end 2025.","Three patients treated with ZEVASKYN in Q1 2026; QTC network expanded to six sites including CHOP and Columbia.","In-licensed ABO-701 (PSMA-SIR-T) engineered T-cell therapy for prostate cancer; IND expected H2 2027.","Deprioritized in-house ophthalmology programs to focus on ZEVASKYN and ABO-701."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":8720000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97956,"accession_number":"0001493152-26-015451","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Abeona Therapeutics appoints Keith Goldan as new independent Board member and Audit Committee Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 9 to 10 members; Goldan appointed as Class 1 director effective April 1, 2026.","Goldan named Chair of Audit Committee; Board determined independence under Nasdaq rules.","Compensation: $50,000 annual cash fee and $150,000 one-time sign-on RSU grant with one-year vesting.","Goldan currently CFO of Syndax Pharmaceuticals; previously CFO at Optinose and Fibrocell."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113172,"accession_number":"0001493152-26-011863","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Abeona Therapeutics adopts amended bylaws raising quorum to 50% and enhancing shareholder proposal rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholder meeting quorum increased from one-third to 50% of shares entitled to vote.","Meetings may be held virtually by remote communication; stockholder list examination requirement eliminated.","Enhanced disclosure and representation requirements for stockholder proposals and director nominations.","Clarified procedures for calling, postponing, rescheduling annual and special meetings.","Added procedural requirements for universal proxy rules compliance under Rule 14a-19."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113171,"accession_number":"0001493152-26-010408","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona reports $71.2M net income in FY 2025; first ZEVASKYN patient treated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First ZEVASKYN commercial patient treated in Dec 2025; net product revenue $2.4M; one patient treated in Q1 2026 with more biopsies collected.","Total revenue $5.8M including $3.4M license revenue from Taysha milestone; PRV sale net gain $152.4M.","Net income $71.2M ($1.34 basic EPS) vs loss of $63.7M in 2024; cash $191.4M as of Dec 31, 2025.","R&D spend decreased to $26.8M; SG&A increased to $65.0M due to commercial transition post-FDA approval.","Expanding patient access: fourth QTC activated at UTMB Galveston; building launch momentum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113170,"accession_number":"0001493152-26-009299","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Abeona reports building ZEVASKYN launch momentum; payer coverage reaches 80% of commercial lives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient treated with ZEVASKYN in Dec 2025; manufacturing resumed Jan 2026, multiple biopsies collected, additional scheduled.","All major commercial payers (United Healthcare, Cigna, Aetna, Anthem, most BCBS) now cover ZEVASKYN, representing ~80% of commercial lives.","CMS established permanent HCPCS J-code (J3389) effective Jan 1, 2026; coverage also secured across all Medicaid programs.","Initial Qualified Treatment Centers gaining familiarity with administrative processes; growing patient and physician interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129564,"accession_number":"0001493152-25-021721","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona Q3 net loss narrows to $5.2M; ZEVASKYN first treatment delayed to Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.2M ($0.10/sh) vs $30.3M ($0.63/sh) in Q3 2024; R&D expense fell to $4.2M, SG&A rose to $19.3M on commercial launch.","Cash $207.5M at Sep 30, expected to fund operations over two years without ZEVASKYN revenue.","First ZEVASKYN patient treatment shifted to Q4 2025 after sterility assay false positive; biopsy collection resumed Nov 2025.","Patient demand growing: 30 eligible patients identified at two QTCs; 12 product order forms received; three centers activated.","Major commercial payers covering ~60% of RDEB patients; CMS J-code effective Jan 1, 2026; ABO-503 accepted into FDA RDEA program."],"consensus_eps_estimate":-0.2958,"consensus_eps_actual":1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":400000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146137,"accession_number":"0001641172-25-023715","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona reports Q2 net income of $108.8M on PRV sale; ZEVASKYN launch on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $108.8M ($2.07 basic EPS) vs $7.4M in Q2 2024; includes $155M gain from PRV sale.","Cash $225.9M expected to fund operations over two years without anticipated ZEVASKYN revenue.","First ZEVASKYN patient treatment expected in Q3 2025; multiple patients identified at QTCs.","100% of prior authorization requests approved; United Healthcare issued favorable coverage policy.","R&D expense fell to $5.9M; SG&A rose to $17.1M due to commercial launch costs."],"consensus_eps_estimate":-0.3893,"consensus_eps_actual":1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":400000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146136,"accession_number":"0001641172-25-020227","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Abeona amends loan with Avenue, cuts interest rate to 11.75% and issues warrants for 16,474 shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Interest rate on senior secured term loan reduced from 13.5% to 11.75% fixed per annum.","Issued warrants to purchase up to 16,474 shares at $6.07 per share, expiring July 18, 2030.","Upon change of control with share price <= 2x exercise price, Warrantholders get shares without payment.","Warrants exercisable cash or cashless, subject to anti-dilution adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146135,"accession_number":"0001641172-25-017460","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["2.01","2.02","8.01","9.01"],"status":"ready","headline":"Abeona closes sale of Rare Pediatric Disease PRV for $155M; cash at $225M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed sale of Rare Pediatric Disease Priority Review Voucher for $155M gross proceeds on June 27, 2025.","Unrestricted cash, equivalents, and short-term investments totaled approximately $225M as of June 30, 2025.","CFO expects over two years of operating capital without further capital infusion; profitability projected early 2026.","First ZEVASKYN patient treatment anticipated in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164453,"accession_number":"0001641172-25-011452","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Abeona Therapeutics holds annual meeting; elects three Class 3 directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mark J. Alvino, Faith L. Charles, and Donald A. Wuchterl elected as Class 3 directors.","Alvino received 26,260,868 votes for, Charles 26,774,705, Wuchterl 26,856,990.","Advisory vote on NEO compensation approved: 25,777,223 for, 1,552,881 against.","Ratification of Deloitte & Touche as auditor for FY 2025 approved: 34,334,516 for.","All proposals passed with broker non-votes on director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164452,"accession_number":"0001641172-25-010514","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona Q1 net loss $12M; ZEVASKYN approved Apr 28, PRV sold for $155M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.0M ($0.24/share) vs. $31.6M ($1.16/share) in Q1 2024; no revenue yet.","FDA approved ZEVASKYN on Apr 28; first QTC (Lurie Children’s) activated, first patient expected Q3 2025.","Entered asset purchase agreement to sell rare pediatric disease PRV for gross proceeds of $155M.","Cash and investments $84.5M at Mar 31, 2025; PRV proceeds to extend runway into early 2026.","~30 patients registered in Abeona Assist; value-based agreements with payers covering ~100M lives."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164451,"accession_number":"0001641172-25-009564","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Abeona Therapeutics sells PRV for $155M cash; expects profitability early 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Definitive agreement to sell Rare Pediatric Disease PRV for $155M in gross cash proceeds at closing.","PRV awarded by FDA on April 28, 2025 upon approval of ZEVASKYN (prademagene zamikeracel) for RDEB.","CFO: proceeds provide over two years of operating expenses without additional financing; ZEVASKYN launch Q3 2025.","Expects profitability in early 2026; closing subject to HSR waiting period; Stifel and Jefferies as advisors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164450,"accession_number":"0001641172-25-006584","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Abeona Therapeutics files 8-K with webcast presentation; no material financial data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Webcast presentation furnished as Exhibit 99.1; content not provided in this filing text.","No revenue, guidance, or clinical update included in the 8-K filing.","Investor call scheduled for April 29, 2025 at 8:00 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164449,"accession_number":"0001641172-25-006548","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Abeona's ZEVASKYN, first cell-based gene therapy for RDEB","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["81% of ZEVASKYN-treated wounds achieved ≥50% healing at 6 months vs 16% control (P<0.0001) in Phase 3 VIITAL study.","Rare Pediatric Disease Priority Review Voucher granted; company plans to monetize the PRV.","ZEVASKYN available through Qualified Treatment Centers starting 3Q 2025; Abeona Assist support program launched.","CEO cites pivotal moment for RDEB community; single surgical application aims for long-term wound healing and pain reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182208,"accession_number":"0001493152-25-010981","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona Therapeutics reports FY2024 net loss $63.7M, cash $98.1M, pz-cel PDUFA April 29","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $63.7M ($1.55 per share) for FY2024 vs $54.2M ($2.53 per share) in FY2023.","Cash and investments total $98.1M as of Dec 31, 2024, up from $52.6M; runway into 2026.","FDA PDUFA target action date for pz-cel BLA is April 29, 2025; draft label received March 14.","If approved, first patient treatment with pz-cel expected in Q3 2025; launch prep with five QTCs underway.","Two additional patents for pz-cel extend protection to June 2037 and July 2040."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198837,"accession_number":"0001493152-24-051060","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve Abeona equity plan share increase from 3.2M to 8.4M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting on Dec 20, 2024: 56.35% quorum with 24,567,979 shares represented.","Proposal 1 approved: 20,996,641 for, 2,876,261 against, 695,077 abstentions, 0 broker non-votes.","Second A&R Plan increases authorized shares for issuance from 3,200,000 to 8,400,000 common shares.","Proposal 2 (adjournment) not voted due to sufficient votes for Proposal 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198836,"accession_number":"0001493152-24-045338","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona Q3 net loss $30.3M; FDA sets pz-cel PDUFA Apr 29, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q3 2024: $30.3M vs $11.8M YoY; includes $15.2M warrant revaluation loss.","Cash, equivalents and investments $110.0M; down $13M from Q2; cash runway into 2026.","FDA accepted pz-cel BLA resubmission; PDUFA target action date April 29, 2025.","CMS granted pz-cel product-specific code and Pre-MDC MS-DRG 018 reimbursement.","New U.S. patent issued for pz-cel (exp. 2037); lease for added manufacturing capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198835,"accession_number":"0001493152-24-044514","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Abeona Therapeutics: FDA accepts BLA resubmission for pz-cel; PDUFA date April 29, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted for review Abeona's resubmitted BLA for pz-cel (autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa).","PDUFA target action date assigned: April 29, 2025.","Resubmission supported by Phase 3 VIITAL and Phase 1/2a data with up to 8 years of follow-up.","If approved, pz-cel would be first autologous cell-based gene therapy for RDEB; Abeona may be eligible for a Priority Review Voucher."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198834,"accession_number":"0001493152-24-042775","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Abeona Therapeutics resubmits BLA for pz-cel gene therapy for RDEB to FDA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resubmitted Biologics License Application (BLA) for pz-cel to FDA for recessive dystrophic epidermolysis bullosa (RDEB).","Resubmission addresses all Chemistry Manufacturing and Controls (CMC) items from April 2024 Complete Response Letter.","No new clinical trials or data requested; prior CRL had no deficiencies in safety or efficacy.","FDA expected to set new PDUFA target action date; review period is 2 or 6 months based on classification.","Pz-cel holds Regenerative Medicine Advanced Therapy, Breakthrough, Orphan, and Rare Pediatric Disease designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214878,"accession_number":"0001493152-24-031862","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Abeona Therapeutics appoints Drs. Zeiher and Crombez to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bernhardt G. Zeiher, MD appointed as Class 1 director; Eric Crombez, MD as Class 2 director; both independent.","Zeiher is former CMO of Astellas Pharma with 20+ years of drug development; Crombez is CMO of Ultragenyx and FDA advisory committee member.","Each director receives $50,000 annual cash retainer and $55,000 one-time RSAs with one-year vesting.","Appointments effective August 8, 2024 (Zeiher) and August 12, 2024 (Crombez).","Additions come as Abeona focuses on pz-cel gene therapy for RDEB and pipeline expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214877,"accession_number":"0001493152-24-031146","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona reports Q2 net income of $7.4M; FDA aligned on pz-cel BLA resubmission for 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $7.4M in Q2 2024 (includes $24.9M gain on warrant liabilities) vs net loss of $16.7M in Q2 2023.","Cash, cash equivalents, short-term investments and restricted cash total $123.0M as of June 30, 2024.","Completed Type A meeting with FDA; preliminary alignment on CMC items; BLA resubmission for pz-cel on track for 2H 2024.","Upon BLA acceptance, FDA expected to set PDUFA action date six months from submission date.","Closed $75M underwritten securities offering in May 2024; $50M credit facility available; cash runway into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214876,"accession_number":"0001493152-24-026640","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Abeona Therapeutics amends bylaws to allow 24-hour notice for special board meetings via electronic transmission","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amendment and restatement of bylaws on July 5, 2024, effective July 8, 2024.","Special board meetings can now be called with at least 24 hours' notice personally or by telephone, email, or other electronic means.","No other material changes to the bylaws disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234055,"accession_number":"0001493152-24-019449","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona Q1 net loss $31.6M; BLA resubmission expected H2 2024; closed $75M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $31.6M ($1.16/share) vs. $9.1M loss a year ago; cash $62.7M at March 31, up from $52.6M.","Closed $75M underwritten offering on May 7, 2024; cash runway extended into 2026.","FDA CRL in April 2024 cited CMC deficiencies; no efficacy/safety issues; BLA resubmission planned H2 2024.","R&D expense $7.2M (down 10% YoY); G&A expense $7.1M (up 78% YoY).","Entered $50M credit facility in Jan 2024, drew $20M first tranche."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234054,"accession_number":"0001493152-24-017768","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Abeona Therapeutics prices $75M underwritten offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering: 12,285,056 common shares at $4.07/share and 6,142,656 pre-funded warrants at $4.0699 each.","Gross proceeds ~$75M; net proceeds ~$70.2M after underwriting discounts and expenses.","Closing expected May 7, 2024; Stifel is sole bookrunner.","Proceeds to fund BLA resubmission and commercialization of pz-cel, plus working capital.","New and existing investors participating include Adage Capital, Janus Henderson, Nantahala, Suvretta, Vivo Capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234053,"accession_number":"0001493152-24-017625","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Abeona reports preliminary Q1 cash $62.7M; terminates $106M ATM prospectus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents, and investments of $62.7M as of March 31, 2024.","Terminated June 2023 ATM prospectus covering up to $106M in common shares.","No sales under Sales Agreement until a new prospectus or registration statement is filed.","Sales Agreement itself remains in effect; only the specific supplement is suspended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234052,"accession_number":"0001493152-24-015792","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Abeona shareholders approve equity plan increase to 3.2M shares; re-elect two directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["A&R 2023 Equity Incentive Plan approved, increasing shares reserved from 1.7M to 3.2M (1.5M new shares).","Leila Alland and Vishwas Seshadri re-elected as Class 2 directors with overwhelming support.","Advisory vote on named executive officer compensation approved: 9,529,727 for, 402,844 against.","Ratification of Deloitte & Touche as independent auditor for FY2024 approved: 14,720,159 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234051,"accession_number":"0001493152-24-015531","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Abeona receives FDA Complete Response Letter for pz-cel BLA due to CMC deficiencies","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CRL for pz-cel BLA cites additional CMC information needed; no clinical efficacy/safety deficiencies.","No new clinical trials or clinical data requested by FDA for approval.","Company expects to complete BLA resubmission with requested CMC data in Q3 2024.","PDUFA date of May 25, 2024 will be missed due to proposed timing of data submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252005,"accession_number":"0001493152-24-010206","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona Therapeutics reports FY2023 results; FDA completes pz-cel PLI with Form 483, PDUFA May 25, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA completed Pre-License Inspection of Cleveland manufacturing facility; Form 483 issued for process controls; company submitted response.","Clinical site inspections (Stanford, UMass) for Phase 3 VIITAL study completed with no Form 483 observations.","Net loss $54.2M ($2.53 per share) for FY2023; revenue $3.5M from Taysha license milestone.","Cash and investments $52.6M at Dec 31, 2023; received $20M tranche from $50M Avenue credit facility in Jan 2024.","Cash runway estimated into Q1 2025, excluding potential pz-cel commercial revenue or PRV sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252004,"accession_number":"0001493152-24-001660","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Abeona secures $50M credit facility; $20M funded at close for pz-cel launch prep","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$50M term loan from Avenue Venture Opportunities; $20M drawn at Jan 8 close, $10M committed after pz-cel approval, $20M discretionary.","Loans mature July 1, 2027; interest at prime+5% (floor 13.5%); final payment fee 5%; minimum $5M cash covenant.","Warrants issued to lenders for up to ~$2.4M of ABEO stock; exercise price ≤$4.75; expire Jan 2029; cashless exercise allowed.","Proceeds for pz-cel launch and general corporate; PDUFA for pz-cel BLA set for May 25, 2024 (Priority Review)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269540,"accession_number":"0001493152-23-042711","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts and grants Priority Review for Abeona's pz-cel BLA; PDUFA date May 25, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted BLA for pz-cel (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa (RDEB) with Priority Review.","PDUFA target action date set for May 25, 2024.","FDA does not currently plan to hold an Advisory Committee meeting for pz-cel BLA.","BLA supported by data from Phase 3 VIITAL study and Phase 1/2a study showing sustained wound healing and pain reduction.","Priority Review grants eligibility for a Priority Review Voucher."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269539,"accession_number":"0001493152-23-040318","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona submits BLA for pz-cel; Q3 net loss $11.8M, cash $54.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $11.8M ($0.48/share) vs $6.4M ($1.00/share) in Q3 2022.","Cash and short-term investments $54.1M; estimated runway into Q4 2024.","BLA for pz-cel (gene therapy for RDEB) submitted in September; FDA decision expected late-Nov 2023.","Raised $25M in July registered direct offering; commercial launch prep underway.","Appointed Madhav Vasanthavada as Chief Commercial Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":3500000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269538,"accession_number":"0001493152-23-037561","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Abeona Therapeutics dismisses Whitley Penn, appoints Deloitte as auditor effective Oct 17, 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Deloitte & Touche LLP engaged as independent registered public accounting firm for FY 2023.","Whitley Penn LLP dismissed as auditor effective October 16, 2023, with no disagreements or reportable events.","Whitley Penn's reports on 2022 and 2021 financials were unqualified and not modified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286520,"accession_number":"0001493152-23-027107","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona Therapeutics Q2 net loss $16.7M; on track for EB-101 BLA submission in Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.7M ($0.92/share) vs $7.9M ($1.36/share) in Q2 2022; revenue $3.5M from license.","Cash $37.1M at June 30; $25M July offering extends runway into Q4 2024.","BLA submission for EB-101 in RDEB on track for Q3 2023; pre-BLA briefing submitted to FDA.","Completed Process Performance Qualification runs for commercial production of EB-101.","Additional Phase 3 VIITAL efficacy/safety data presented at ISID and SPD meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":3500000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286519,"accession_number":"0001493152-23-023908","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2023-07-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Abeona closes $25M direct offering; proceeds to fund EB-101 commercialization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $25M from sale of 3.28M shares and 2.92M pre-funded warrants at $4.03 per share.","Offering led by Nantahala Capital Management with participation by Adage Capital Partners and other existing investors.","Net proceeds to fund commercialization of EB-101 and extend cash runway into Q4 2024.","Company expects to qualify for a priority review voucher upon potential BLA approval in H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286518,"accession_number":"0001493152-23-023235","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Abeona raises $25M in registered direct offering at $4.03/share to fund EB-101 launch prep","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$25M; net ~$22.9M after fees and expenses.","Issued 3,284,407 shares and pre-funded warrants for 2,919,140 shares at $4.03 per share.","Proceeds primarily for commercial launch preparation for gene therapy EB-101 (BLA pending).","Offering led by Nantahala Capital Management; includes Adage Capital Partners and two other institutions.","Closing expected on or about July 6, 2023, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306429,"accession_number":"0001493152-23-017946","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Abeona shareholders elect directors, approve 2023 equity plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Michael Amoroso (6.5M for) and Christine Silverstein (6.2M for) elected Class I directors until 2026.","Abeona Therapeutics 2023 Equity Incentive Plan approved: 6.2M for, 569K against, 18K abstentions.","Advisory vote on named executive officer compensation passed: 6.4M for, 282K against, 37K abstentions.","Ratification of Whitley Penn LLP as independent auditor for FY2023 passed: 10.4M for, 49K against, 28K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306428,"accession_number":"0001493152-23-016277","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona Therapeutics Q1 net loss $9.1M; cash runway into Q3 2024; advancing EB-101 BLA submission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.1M ($0.54 loss per share) vs $22.0M ($3.80) in Q1 2022; license revenue nil.","Cash, equivalents, short-term investments $40.7M at Mar 31, 2023, down from $52.5M at Dec 31, 2022; cash runway into Q3 2024.","Progress toward BLA submission for EB-101 in RDEB in late Q2/early Q3 2023; pre-BLA meeting request submitted to FDA.","Additional Phase 3 VIITAL data presented at ISID; preclinical AAV ophthalmology data (ABO-504, ABO-503, ABO-505) at ASGCT May 16-20.","R&D expenses $8.0M, G&A $4.0M for Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306427,"accession_number":"0001493152-23-011838","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2023-04-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Abeona Therapeutics reduces board size to seven; Chairman moves director class for compliance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board size decreased from nine to seven directors, effective at 2023 Annual Shareholder Meeting.","Chairman Michael Amoroso relinquished Class 2 seat and was appointed Class 1 director to maintain equal class sizes.","Amoroso's service is deemed continuous; no new compensatory arrangements were entered into."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325568,"accession_number":"0001493152-23-009382","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona Therapeutics FY2022 net loss narrows to $43.5M; EB-101 BLA submission on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $43.5M ($5.53/share) vs $84.9M ($21.57/share) in FY2021 as expense reductions offset lower revenue.","Cash of $52.5M at Dec 31, 2022 ($50.9M at Dec 31, 2021); expected to fund operations into Q3 2024.","Plans to submit BLA for EB-101 (RDEB) to FDA in late Q2/early Q3 2023, based on positive Phase 3 VIITAL results.","Appointed Dmitriy Grachev as CMO; Madhav Vasanthavada as VP Business Development; Amanda Moore promoted to VP.","Completed $35M private placement in November 2022 with institutional investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325567,"accession_number":"0001493152-23-007341","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Abeona confirms no cash or securities at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company holds no cash deposits or securities at Silicon Valley Bank.","Filed on March 13, 2023, during the SVB collapse.","Disclosure addresses investor concerns about exposure to SVB.","No further details or financial impact provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343306,"accession_number":"0001493152-22-031599","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona Q3 net loss $9.5M; Phase 3 EB-101 meets endpoints, BLA submission planned Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.5M ($1.48 loss per share) for Q3 2022, compared to $7.0M loss in Q3 2021.","Cash, equivalents and investments totaled $23.5M at Sept 30, 2022; subsequent $35M private placement extends runway into Q3 2024.","Phase 3 VIITAL trial of EB-101 for RDEB met both co-primary endpoints with statistically significant wound healing and pain reduction.","Company plans to submit BLA to FDA for EB-101 in Q2 2023; possible Priority Review Voucher eligibility upon approval.","R&D expenses decreased to $5.5M from $9.1M year-over-year; G&A expenses down to $3.9M from $5.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1346000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343305,"accession_number":"0001493152-22-030374","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Abeona raises $35M in private placement; Phase 3 EB-101 trial meets endpoints","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $35M from sale of 7.07M shares, pre-funded warrants for 0.54M shares, and common warrants for 7.61M shares.","Offering price per unit $4.60; common warrants exercisable at $4.75 per share for five years.","Phase 3 VIITAL trial for EB-101 met co-primary, secondary, and exploratory endpoints with high statistical significance.","Net proceeds plus existing resources expected to fund operations into Q3 2024.","Placement includes new and existing investors: Adage Capital, Armistice Capital, Deerfield, EcoR1, Nantahala."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343304,"accession_number":"0001493152-22-030288","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Abeona Phase 3 VIITAL study of EB-101 meets co-primary endpoints; BLA submission planned Q2 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["81.4% of treated wounds achieved ≥50% healing vs 16.3% controls (p<0.0001).","Pain reduction co-primary endpoint met: mean reduction 3.07 treated vs 0.90 control (p=0.0002).","No serious treatment-related adverse events; consistent with past safety profile.","BLA submission to FDA for EB-101 in RDEB targeted for Q2 2023.","EB-101 has Orphan Drug and Rare Pediatric Disease designations, may qualify for Priority Review Voucher."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359856,"accession_number":"0001493152-22-023332","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2022-08-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Abeona shareholders elect three Class 3 directors, approve equity plan amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class 3 directors elected: Alvino (1.25M for), Charles (1.34M for), Wuchterl (1.35M for).","Equity plan amendment approved (987K for, 648K against), doubling authorized shares to 1.44M.","Say-on-pay approved (1.26M for, 372K against); shareholders favored 1-year frequency for future votes.","Whitley Penn ratified as auditor with 2.94M votes for, 56K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359855,"accession_number":"0001493152-22-021966","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abeona Q2 net loss $12.1M; cash runway to 2Q 2023; VIITAL data expected late Q3/early Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.1M ($2.08 loss/share) vs $15.2M ($3.93 loss/share) in Q2 2021.","Cash and investments $26.0M; net cash used in ops $9.0M; runway extended into Q2 2023.","License revenue $1.0M from Taysha sublicense milestone; R&D $6.7M, G&A $3.5M.","Phase 3 VIITAL study for EB-101 topline data expected late Q3/early Q4 2022; last patient monitoring mid-September.","License agreement with Ultragenyx for ABO-102 (MPS IIIA); Abeona eligible for tiered royalties and milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":5.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":1346000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359854,"accession_number":"0001493152-22-019883","cik":318306,"company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","form_type":"8-K","filed_at":"2022-07-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Abeona regains Nasdaq compliance with minimum bid price requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notification on July 19, 2022 confirming compliance with Listing Rule 5550(a)(2).","Minimum $1.00 closing bid price was maintained for 10 consecutive trading days through July 18, 2022.","Matter is now closed; common stock will continue trading on Nasdaq Capital Market.","Press release issued July 20, 2022 announcing the compliance regain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":326867153.50087875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-07-20T23:59:59+00:00|359854"}